CO2024012057A2 - Elementos reguladores de gjb2 y usos de los mismos - Google Patents

Elementos reguladores de gjb2 y usos de los mismos

Info

Publication number
CO2024012057A2
CO2024012057A2 CONC2024/0012057A CO2024012057A CO2024012057A2 CO 2024012057 A2 CO2024012057 A2 CO 2024012057A2 CO 2024012057 A CO2024012057 A CO 2024012057A CO 2024012057 A2 CO2024012057 A2 CO 2024012057A2
Authority
CO
Colombia
Prior art keywords
gjb2
promoters
hearing loss
regulatory elements
enhancers
Prior art date
Application number
CONC2024/0012057A
Other languages
English (en)
Spanish (es)
Inventor
Gabriela Pregernig
Joseph Burns
Kathryn Ellis
Tyler Gibson
Kevin Lebo
Samuelson Meghan Drummond
Sarah Cancelarich
Leah Sabin
Battista Miani Daniela Di
Original Assignee
Regeneron Pharma
Decibel Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma, Decibel Therapeutics Inc filed Critical Regeneron Pharma
Publication of CO2024012057A2 publication Critical patent/CO2024012057A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0046—Ear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Toxicology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CONC2024/0012057A 2022-02-04 2024-09-04 Elementos reguladores de gjb2 y usos de los mismos CO2024012057A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263306941P 2022-02-04 2022-02-04
US202263306928P 2022-02-04 2022-02-04
PCT/US2023/061953 WO2023150689A2 (en) 2022-02-04 2023-02-03 Gjb2 regulatory elements and uses thereof

Publications (1)

Publication Number Publication Date
CO2024012057A2 true CO2024012057A2 (es) 2024-09-30

Family

ID=87552983

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2024/0012057A CO2024012057A2 (es) 2022-02-04 2024-09-04 Elementos reguladores de gjb2 y usos de los mismos

Country Status (11)

Country Link
US (1) US20250127928A1 (cg-RX-API-DMAC10.html)
EP (1) EP4473005A4 (cg-RX-API-DMAC10.html)
JP (1) JP2025506419A (cg-RX-API-DMAC10.html)
KR (1) KR20240156606A (cg-RX-API-DMAC10.html)
AU (1) AU2023214481A1 (cg-RX-API-DMAC10.html)
CA (1) CA3250345A1 (cg-RX-API-DMAC10.html)
CL (1) CL2024002306A1 (cg-RX-API-DMAC10.html)
CO (1) CO2024012057A2 (cg-RX-API-DMAC10.html)
IL (1) IL314705A (cg-RX-API-DMAC10.html)
MX (1) MX2024009520A (cg-RX-API-DMAC10.html)
WO (1) WO2023150689A2 (cg-RX-API-DMAC10.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20260027327A1 (en) 2024-07-26 2026-01-29 Regeneron Pharmaceuticals, Inc. Otic drug delivery system and methods

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI896570B (zh) * 2019-10-30 2025-09-11 美商迪賽博治療公司 使用耳畸蛋白雙載體系統治療感覺神經性聽力損失之組合物及方法
CN116096900A (zh) * 2020-05-13 2023-05-09 阿库斯股份有限公司 用于治疗gjb2相关听力损失的组合物和方法

Also Published As

Publication number Publication date
KR20240156606A (ko) 2024-10-30
MX2024009520A (es) 2024-09-11
EP4473005A2 (en) 2024-12-11
US20250127928A1 (en) 2025-04-24
WO2023150689A3 (en) 2023-11-16
CL2024002306A1 (es) 2024-12-27
JP2025506419A (ja) 2025-03-11
IL314705A (en) 2024-10-01
CA3250345A1 (en) 2023-08-10
WO2023150689A8 (en) 2023-10-12
EP4473005A4 (en) 2026-02-18
WO2023150689A2 (en) 2023-08-10
AU2023214481A1 (en) 2024-08-08

Similar Documents

Publication Publication Date Title
CL2023000294A1 (es) Expresión selectiva de un transgene de tejidos
CY1125196T1 (el) Γενετικα τροποποιημενοι ποντικοι εκφραζοντες χιμαιρικα μορια μειζονος συμπλεγματος ιστοσυμβατοτητας (mhc) ii
CO2020010376A2 (es) Uso de vectores lentivirales que expresan el factor viii
CO2021006060A2 (es) Generación de pah humana mejorada para el tratamiento de pku grave mediante terapia de sustitución de genes dirigida al hígado
CO2023016804A2 (es) Composiciones y métodos para el tratamiento de la pérdida auditiva neurosensorial mediante el uso de sistemas de vectores duales de estereocilina
ECSP17059343A (es) ARNi VARIANTE
PE20190335A1 (es) Receptores de celulas t
MX2021011037A (es) Vectores de adn no virales y usos de estos para expresar agentes terapéuticos de fenilalanina hidroxilasa (pah).
RU2017111300A (ru) Центральные т-клетки памяти для адоптивной т-клеточной терапии
MX2018001529A (es) Animales resistentes a patogenos que tienen genes cd163 modificados.
MX2022001201A (es) Ratones con genes insertados de sirp¿-il15 humanizadas y métodos para usarlos.
MX2021011039A (es) Vectores de adn no virales y usos de estos para expresar agentes terapéuticos con fviii.
CL2022003147A1 (es) Composiciones y métodos para tratar pérdida auditiva asociada con gjb2
MX2025006880A (es) Metodos para generar celulas madre hematopoyeticas
CL2024002306A1 (es) Elementos reguladores de gjb2 y usos de los mismos.
MX2018006373A (es) Produccion de virus en cultivos celulares.
MX2024004443A (es) Promotores de estereocilina y usos de estos.
DOP2025000286A (es) Composiciones para tratae la pérdida de audición y/o la pérdida de visión asociada a clrn1
CO2021015405A2 (es) Expresión de proteínas de unión a antígenos en el sistema nervioso
MX2024003910A (es) Composiciones de administración de terapia génica y métodos para tratar la pérdida auditiva.
ECSP22049399A (es) C?lula vector adyuvante artificial con contenido de ny?eso?1 para usar en el tratamiento del c?ncer
MX2022004799A (es) Composiciones y metodos para el tratamiento de los trastornos de almacenamiento de glucogeno.
AR133384A1 (es) Anti-tfr:esfingomielinasa ácida para el tratamiento de la deficiencia de esfingomielinasa ácida
MX2021010998A (es) Metodos para mejorar la eficacia en el agotamiento de celulas tcr a?+.
MX2024002948A (es) Composiciones y métodos para tratar o prevenir enfermedades autoinmunes.